EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders (Q38394577)

2 September 2017

1 reference

title

EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders (English)

1 reference

2 September 2017

1 reference

2 September 2017

D Firinu

0 references

O Boyman

0 references

O Palomares

0 references

A Bossios

0 references

E Knol

0 references

Carsten B Schmidt-Weber

C Schmidt-Weber

0 references

C Kaegi

1 reference

2 September 2017

M Akdis

1 reference

2 September 2017

S Bavbek

1 reference

2 September 2017

A Chatzipetrou

1 reference

2 September 2017

T Eiwegger

1 reference

2 September 2017

T Harr

1 reference

2 September 2017

A Matucci

1 reference

2 September 2017

U C Steiner

1 reference

2 September 2017

A Vultaggio

1 reference

2 September 2017

C A Akdis

1 reference

2 September 2017

F Spertini

1 reference

2 September 2017

publication date

24 April 2015

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

727-754

1 reference

Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome

2 September 2017

cites work

1 reference

Innate and adaptive immune responses in asthma

21 January 2018

1 reference

Therapies for allergic inflammation: refining strategies to induce tolerance

21 January 2018

1 reference

Effects of omalizumab on markers of inflammation in patients with allergic asthma

21 January 2018

1 reference

How are T(H)2-type immune responses initiated and amplified?

21 January 2018

1 reference

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

21 January 2018

1 reference

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

21 January 2018

1 reference

B-cell targeted therapies in human autoimmune diseases: an updated perspective

21 January 2018

1 reference

Lebrikizumab Treatment in Adults with Asthma

21 January 2018

1 reference

Tralokinumab for uncontrolled asthma

21 January 2018

1 reference

Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27.

21 January 2018

1 reference

Structure and signalling in the IL-17 receptor family

21 January 2018

1 reference

Marketing approval of mogamulizumab: a triumph for glyco-engineering

21 January 2018

1 reference

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial

21 January 2018

1 reference

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

21 January 2018

1 reference

Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma

21 January 2018

1 reference

Omalizumab: Anti-IgE therapy in allergy

21 January 2018

1 reference

Can anti-IgE therapy prevent airway remodeling in allergic asthma?

21 January 2018

1 reference

Italian real-life experience of omalizumab.

21 January 2018

1 reference

Omalizumab: a review of its use in patients with severe persistent allergic asthma

21 January 2018

1 reference

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma

21 January 2018

1 reference

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

21 January 2018

1 reference

Future forms of immunotherapy

21 January 2018

1 reference

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

21 January 2018

1 reference

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

21 January 2018

1 reference

Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention

21 January 2018

1 reference

Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor

21 January 2018

1 reference

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

The potential of biologics for the treatment of asthma

21 January 2018

1 reference

IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist

21 January 2018

1 reference

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

21 January 2018

1 reference

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

21 January 2018

1 reference

Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma

21 January 2018

1 reference

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

Reslizumab for Poorly Controlled, Eosinophilic Asthma

21 January 2018

1 reference

Novel targeted therapies for eosinophilic disorders

21 January 2018

1 reference

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

21 January 2018

1 reference

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers

21 January 2018

1 reference

A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma

21 January 2018

1 reference

Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.

21 January 2018

1 reference

A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics

21 January 2018

1 reference

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

21 January 2018

1 reference

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma

21 January 2018

1 reference

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

OX40L blockade and allergen-induced airway responses in subjects with mild asthma

21 January 2018

1 reference

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

21 January 2018

1 reference

Evidence of a role of tumor necrosis factor alpha in refractory asthma

21 January 2018

1 reference

The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial.

21 January 2018

1 reference

Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial

21 January 2018

1 reference

The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma

21 January 2018

1 reference

Effects of an anti-TSLP antibody on allergen-induced asthmatic responses

21 January 2018

1 reference

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

21 January 2018

1 reference

Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated

21 January 2018

1 reference

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

21 January 2018

1 reference

Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy

21 January 2018

1 reference

A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

21 January 2018

1 reference

Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy

21 January 2018

1 reference

Future therapies for food allergies

21 January 2018

1 reference

Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report

21 January 2018

1 reference

Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab

21 January 2018

1 reference

Oral immunotherapy for food allergy: towards a new horizon

21 January 2018

1 reference

Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab.

21 January 2018

1 reference

High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.

21 January 2018

1 reference

Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis.

21 January 2018

1 reference

Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria

21 January 2018

1 reference

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

21 January 2018

1 reference

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

21 January 2018

1 reference

Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis

21 January 2018

1 reference

Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria

21 January 2018

1 reference

Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy

21 January 2018

1 reference

Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE.

21 January 2018

1 reference

Successful treatment of solar urticaria with anti-immunoglobulin E therapy

21 January 2018

1 reference

Treatment of chronic autoimmune urticaria with omalizumab

21 January 2018

1 reference

Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria

21 January 2018

1 reference

Therapy of autoinflammatory syndromes

21 January 2018

1 reference

Biologic drugs in autoinflammatory syndromes

21 January 2018

1 reference

Schnitzler's syndrome: diagnosis, treatment, and follow-up

21 January 2018

1 reference

Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study

21 January 2018

1 reference

Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome

21 January 2018

1 reference

Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study

21 January 2018

1 reference

TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients

21 January 2018

1 reference

Alefacept for moderate to severe atopic dermatitis: a pilot study in adults.

21 January 2018

1 reference

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases.

21 January 2018

1 reference

Efalizumab for severe atopic dermatitis: a pilot study in adults

21 January 2018

1 reference

New era of biologic therapeutics in atopic dermatitis

21 January 2018

1 reference

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

21 January 2018

1 reference

Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab

21 January 2018

1 reference

Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis

21 January 2018

1 reference

Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis

21 January 2018

1 reference

Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence

21 January 2018

1 reference

Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab.

21 January 2018

1 reference

Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

Churg-Strauss vasculitis in a patient treated with omalizumab

21 January 2018

1 reference

Successful management of Churg-Strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case

21 January 2018

1 reference

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis

21 January 2018

1 reference

Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps

21 January 2018

1 reference

Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia

21 January 2018

1 reference

Novel targeted therapies for eosinophil-associated diseases and allergy

21 January 2018

1 reference

Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody

21 January 2018

1 reference

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

21 January 2018

1 reference

Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes

21 January 2018

1 reference

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome

21 January 2018

1 reference

Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome

21 January 2018

1 reference

Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.

21 January 2018

1 reference

An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis

21 January 2018

1 reference

Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis

21 January 2018

1 reference

Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor

21 January 2018

1 reference

Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

Adverse reactions to biologic agents and their medical management.

21 January 2018

1 reference

21 January 2018

1 reference

Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

21 January 2018

1 reference

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

21 January 2018

1 reference

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

21 January 2018

1 reference

A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma

21 January 2018

1 reference

Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

21 January 2018

1 reference

The risk of infections with biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

The consequences of not having eosinophils.

21 January 2018

1 reference

Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria

21 January 2018

1 reference

21 January 2018

1 reference

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

Effects of omalizumab in Aspergillus-associated airway disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ALL.12616

1 reference

2 September 2017

1 reference